Helus Pharma

Helus Pharma is a clinical-stage biopharmaceutical company originally established as a specialized vehicle by Everest Medicines to advance the development of renal therapies, most notably Nefecon (HL-001). Headquartered in Shanghai with research operations in San Diego, the company focuses on addressing high unmet needs in chronic kidney disease and immunology. Its lead product, Nefecon, is a targeted-release formulation of budesonide developed for the treatment of IgA Nephropathy and has successfully transitioned through Phase 3 clinical trials to regulatory approval in China. In 2022, Everest Medicines consolidated its ownership by acquiring the remaining stakes in Helus Pharma for approximately $117 million, integrating its renal portfolio into the parent company's broader pipeline. Helus Pharma remains a key entity in the commercialization and continued clinical expansion of innovative nephrology treatments.